Carey E Gleason1,2,3, Derek Norton3,4, Eric D Anderson5, Michelle Wahoske1,3, Danielle T Washington1,2,3, Emre Umucu6, Rebecca L Koscik7, N Maritza Dowling8, Sterling C Johnson1,2,3,8, Cynthia M Carlsson1,2,3,8, Sanjay Asthana1,2,3,8. 1. Division of Geriatrics and Gerontology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 2. Geriatric Research, Education and Clinical Center (11G), William S. Middleton Memorial Veterans Hospital, Madison, WI, USA. 3. Wisconsin Alzheimer's Disease Research Center, Madison, WI, USA. 4. University of Wisconsin, Department of Biostatistics and Medical Informatics, Madison, WI, USA. 5. Wright State University, School of Education and Human Services, Dayton, OH, USA. 6. Department of Rehabilitation Sciences, University of Texas at El Paso, El Paso, TX, USA. 7. Wisconsin Alzheimer's Institute, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA. 8. George Washington University, School of Nursing, Washington, DC, USA.
Abstract
BACKGROUND: Alzheimer's disease (AD) biomarkers are emerging as critically important for disease detection and monitoring. Most biomarkers are obtained through invasive, resource-intense procedures. A cognitive marker, intra-individual cognitive variability (IICV) may provide an alternative or adjunct marker of disease risk for individuals unable or disinclined to undergo lumbar puncture. OBJECTIVE: To contrast risk of incident AD and mild cognitive impairment (MCI) associated with IICV to risk associated with well-established biomarkers: cerebrospinal fluid (CSF) phosphorylated tau protein (p-tau181) and amyloid-β 42 (Aβ42) peptide. METHODS: Dispersion in cognitive performance, IICV, was estimated with a published algorithm, and included Trail Making Test A and B, Rey Auditory Verbal Learning Test (RAVLT), and the American National Adult Reading Test (ANART). CSF biomarkers were expressed as a ratio: p-tau181/Aβ42, wherein high values signified pathognomonic profiles. Logistic regression models included longitudinal data from 349 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants who completed lumbar puncture. All subjects were cognitively healthy (n = 105) or diagnosed with MCI (n = 244) at baseline. We examined odds of conversion associated with baseline elevations in IICV and/or ratio of CSF p-tau181/Aβ42. RESULTS: When included in models alone or in combination with CSF p-tau181/Aβ42, one standard IICV unit higher was associated with an estimated odds ratio for incident AD or MCI of 2.81 (95% CI: 1.83-4.33) in the most inclusive sample, and an odds ratio of 3.41 (95% CI: 2.03-5.73) when restricted to participants with MCI. Iterative analyses suggested that IICV independently improved model fit even when individual index components were included in comparative models. CONCLUSIONS: These analyses provide preliminary support for IICV as a marker of incident AD and MCI. This easily-disseminated, non-invasive marker compared favorably to well-established CSF biomarkers.
BACKGROUND:Alzheimer's disease (AD) biomarkers are emerging as critically important for disease detection and monitoring. Most biomarkers are obtained through invasive, resource-intense procedures. A cognitive marker, intra-individual cognitive variability (IICV) may provide an alternative or adjunct marker of disease risk for individuals unable or disinclined to undergo lumbar puncture. OBJECTIVE: To contrast risk of incident AD and mild cognitive impairment (MCI) associated with IICV to risk associated with well-established biomarkers: cerebrospinal fluid (CSF) phosphorylated tau protein (p-tau181) and amyloid-β 42 (Aβ42) peptide. METHODS: Dispersion in cognitive performance, IICV, was estimated with a published algorithm, and included Trail Making Test A and B, Rey Auditory Verbal Learning Test (RAVLT), and the American National Adult Reading Test (ANART). CSF biomarkers were expressed as a ratio: p-tau181/Aβ42, wherein high values signified pathognomonic profiles. Logistic regression models included longitudinal data from 349 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants who completed lumbar puncture. All subjects were cognitively healthy (n = 105) or diagnosed with MCI (n = 244) at baseline. We examined odds of conversion associated with baseline elevations in IICV and/or ratio of CSF p-tau181/Aβ42. RESULTS: When included in models alone or in combination with CSF p-tau181/Aβ42, one standard IICV unit higher was associated with an estimated odds ratio for incident AD or MCI of 2.81 (95% CI: 1.83-4.33) in the most inclusive sample, and an odds ratio of 3.41 (95% CI: 2.03-5.73) when restricted to participants with MCI. Iterative analyses suggested that IICV independently improved model fit even when individual index components were included in comparative models. CONCLUSIONS: These analyses provide preliminary support for IICV as a marker of incident AD and MCI. This easily-disseminated, non-invasive marker compared favorably to well-established CSF biomarkers.
Entities:
Keywords:
Alzheimer’s disease; amyloid beta-protein; biological markers; cerebrospinal fluid; cognition; cognitive dysfunction; incidence studies; mild cognitive impairment; tau protein
Authors: Paul S Aisen; Ronald C Petersen; Michael C Donohue; Anthony Gamst; Rema Raman; Ronald G Thomas; Sarah Walter; John Q Trojanowski; Leslie M Shaw; Laurel A Beckett; Clifford R Jack; William Jagust; Arthur W Toga; Andrew J Saykin; John C Morris; Robert C Green; Michael W Weiner Journal: Alzheimers Dement Date: 2010-05 Impact factor: 21.566
Authors: Sindre Rolstad; Anne Ingeborg Berg; Maria Bjerke; Kaj Blennow; Boo Johansson; Henrik Zetterberg; Anders Wallin Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: Annika Olsson; Hugo Vanderstichele; Niels Andreasen; Geert De Meyer; Anders Wallin; Björn Holmberg; Lars Rosengren; Eugeen Vanmechelen; Kaj Blennow Journal: Clin Chem Date: 2004-11-24 Impact factor: 8.327
Authors: T T Seppälä; O Nerg; A M Koivisto; J Rummukainen; L Puli; H Zetterberg; O T Pyykkö; S Helisalmi; I Alafuzoff; M Hiltunen; J E Jääskeläinen; J Rinne; H Soininen; V Leinonen; S K Herukka Journal: Neurology Date: 2012-04-18 Impact factor: 9.910
Authors: Katherine J Bangen; Alexandra J Weigand; Kelsey R Thomas; Lisa Delano-Wood; Lindsay R Clark; Joel Eppig; Madeleine L Werhane; Emily C Edmonds; Mark W Bondi Journal: Neuropsychology Date: 2019-03-21 Impact factor: 3.295
Authors: Rebecca L Koscik; Derek L Norton; Samantha L Allison; Erin M Jonaitis; Lindsay R Clark; Kimberly D Mueller; Bruce P Hermann; Corinne D Engelman; Carey E Gleason; Mark A Sager; Richard J Chappell; Sterling C Johnson Journal: J Int Neuropsychol Soc Date: 2018-12-07 Impact factor: 2.892
Authors: Tomiko Yoneda; Alejandra Marroig; Eileen K Graham; Emily C Willroth; Tamlyn Watermeyer; Emorie D Beck; Elizabeth M Zelinski; Chandra A Reynolds; Nancy L Pedersen; Scott M Hofer; Daniel K Mroczek; Graciela Muniz-Terrera Journal: Neuropsychology Date: 2021-11-22 Impact factor: 3.295
Authors: Dallas P Veitch; Michael W Weiner; Paul S Aisen; Laurel A Beckett; Charles DeCarli; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; Susan M Landau; John C Morris; Ozioma Okonkwo; Richard J Perrin; Ronald C Petersen; Monica Rivera-Mindt; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; Duygu Tosun; John Q Trojanowski Journal: Alzheimers Dement Date: 2021-09-28 Impact factor: 16.655
Authors: Kelsey R Thomas; Katherine J Bangen; Alexandra J Weigand; Emily C Edmonds; Christina G Wong; Shanna Cooper; Lisa Delano-Wood; Mark W Bondi Journal: Neurology Date: 2019-12-30 Impact factor: 11.800
Authors: Raeanne C Moore; Emily W Paolillo; Erin E Sundermann; Laura M Campbell; Jeremy Delgadillo; Anne Heaton; Joel Swendsen; Colin A Depp Journal: Int J Methods Psychiatr Res Date: 2020-11-07 Impact factor: 4.035